NVS - Novartis Shares Decline As Spin Off Sandoz's Market Debut Falls Short of Expected Valuation | Benzinga
Sandoz Group AG (OTC: SDZNY) (OTC: SDZXF) enters a new era as a standalone player in generic and biosimilar medicines.
Novartis AG's (NYSE: NVS) spin-off was listed and commenced trading today on the SIX Swiss Exchange.
Novartis also reiterated its focused approach to capital allocation, including the ongoing $15 billion share buy-back announced in July 2023 and to continue paying an annual dividend, up from the CHF 3.20 per share paid in 2023, without ...